Business & Tech
Annapolis Biodefense Firm Announces Merger
PharmAthene's merger with a Seattle firm should be complete by the year's end, according to a report.
An Annapolis biodefense firm plans a merger with a Seattle treatment company.
PharmAthene Inc.'s merger with Seattle's Theraclone Sciences Inc. should be complete by the end of the year, The Capital Gazette reports. The combined company will keep PharmAthene's name, but Theraclone CEO Clifford Stocks will serve as president and CEO. The company will keep offices in Seattle and Annapolis.
Theraclone develops therapeutic antibodies to fight infectious diseases.
Find out what's happening in Annapolisfor free with the latest updates from Patch.
“Putting the companies together really deepens the scientific bench and increased the ability for us to be able to execute our current program and for them to execute late stage on their programs," PharmAthene CEO Eric Richman said in a conference call, according to the paper.
Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.
